Evidence map›Paper›PMID 39832483›Full record

ArticleJournal of medicinal chemistry2025

N-Branched Tricyclic Guanidines as Novel Melanocortin-3 Receptor Agonists and Melanocortin-4 Receptor Antagonists.

Nicholas A Weirath, Jonathan W P Zajac, Haley M Donow, Travis M Lavoi, Clemencia Pinilla, Radleigh G Santos, Ritu Prajapati, Robert Speth, Mark D Ericson, Sapna Sarupria and 2 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nicholas A WeirathDepartment of Medicinal Chemistry and the Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0003-4520-5571
Jonathan W P ZajacDepartment of Chemistry and Chemical Theory Center, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Haley M DonowFlorida International University, Port St. Lucie, Florida 34978, United States.
Travis M LavoiFlorida International University, Port St. Lucie, Florida 34978, United States.
Clemencia PinillaDepartment of Medicinal Chemistry and the Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Radleigh G SantosNova Southeastern University, 3301 College Avenue, Fort Lauderdale, Florida 33314, United States.
Ritu PrajapatiDepartment of Medicinal Chemistry and the Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Robert SpethBarry and Judy Silverman College of Pharmacy, Nova Southeastern University, 3300 S. University Dr., Fort Lauderdale, Florida 33328, United States.
Mark D EricsonDepartment of Medicinal Chemistry and the Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-8715-6010
Sapna SarupriaDepartment of Chemistry and Chemical Theory Center, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0001-7692-8313
Marcello A GiulianottiDepartment of Medicinal Chemistry and the Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Carrie Haskell-LuevanoDepartment of Medicinal Chemistry and the Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-6783-5972

Funding

Melanocortin Receptor Selective LigandsR01DK124504 · NIDDK · UNIVERSITY OF MINNESOTA · PI GIULIANOTTI, MARC, HASKELL-LUEVANO, CARRIE · 2021 to 2024
$2.8M
NIDDK NIH HHS R01 DK124504
6 · The paper itself

Abstract

The melanocortin receptors are a class of centrally and peripherally expressed G protein-coupled receptors, of which the MC3R and MC4R subtypes are implicated in the regulation of appetite and energy homeostasis and can serve as potential therapeutic targets for disorders such as obesity and cachexia. An unbiased high-throughput mixture-based library screen was implemented to identify novel ligands with an emphasis on the identification of nanomolar-potent agonists of the mouse melanocortin-3 receptor. This screen yielded the discovery of an N-branched tricyclic guanidine scaffold (TPI2408) that contained three nanomolar potent mMC3R agonists and additional compounds that possessed antagonism for the mMC4R. The antagonist character of this scaffold library at the mMC4R was confirmed by a follow-up positional scanning antagonist screen. Additionally, molecular dynamics simulations herein provide mechanistic insight into the polypharmacological characteristics of melanocortin receptors. The disclosed materials have the potential to serve as important tools and SAR scaffolds in the study of melanocortin receptor function.

Indexed as

Receptor, Melanocortin, Type 3Receptor, Melanocortin, Type 4AnimalsGuanidinesHEK293 CellsHumansMiceMolecular Dynamics SimulationStructure-Activity RelationshipGuanidinesReceptor, Melanocortin, Type 3Receptor, Melanocortin, Type 4

Identifiers

PMID39832483
PMCPMC12150859

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.